Procysbi (Cysteamine Bitartrate) Patent Expiration, LOE Window & CMS Spending

Procysbi (Cysteamine Bitartrate) by Amgen: FDA Orange Book core substance LOE 2027-07-26 (last listed 2037-02-16), 0 AB generics, $121.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayN203389 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2027-07-26
Last Listed Patent or Exclusivity Date2037-02-16
Orange Book Patents (*PED Extensions)24 patents (12 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$121.1M
2024 Medicare Part D Spend$38.0M
2024 Medicaid Spend$83.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.